Can Fite Biopharma Stock Shares Owned By Institutions
| CANF Stock | USD 2.10 0.05 2.44% |
Can Fite Biopharma fundamentals help investors to digest information that contributes to Can Fite's financial success or failures. It also enables traders to predict the movement of Can Stock. The fundamental analysis module provides a way to measure Can Fite's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Can Fite stock.
Can | Shares Owned By Institutions |
Can Fite Biopharma Company Shares Owned By Institutions Analysis
Can Fite's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Can Fite Shares Owned By Institutions | 11.65 % |
Most of Can Fite's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Can Fite Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Can Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Can Fite is extremely important. It helps to project a fair market value of Can Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Can Fite's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Can Fite's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Can Fite's interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 11.65% of Can Fite Biopharma are shares owned by institutions. This is 73.9% lower than that of the Biotechnology sector and 75.47% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 70.29% higher than that of the company.
Can Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Can Fite's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Can Fite could also be used in its relative valuation, which is a method of valuing Can Fite by comparing valuation metrics of similar companies.Can Fite is currently under evaluation in shares owned by institutions category among its peers.
Can Fite Current Valuation Drivers
We derive many important indicators used in calculating different scores of Can Fite from analyzing Can Fite's financial statements. These drivers represent accounts that assess Can Fite's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Can Fite's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 9.3M | 22.2M | 26.2M | 17.2M | 9.5M | 9.0M | |
| Enterprise Value | 6.7M | 14.0M | 21.9M | 14.2M | 5.3M | 5.0M |
Can Fite ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Can Fite's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Can Fite's managers, analysts, and investors.Environmental | Governance | Social |
Can Fundamentals
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (12.96) % | ||||
| Current Valuation | 8.38 M | ||||
| Shares Outstanding | 6.1 M | ||||
| Shares Owned By Institutions | 11.65 % | ||||
| Number Of Shares Shorted | 138.66 K | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 20.05 X | ||||
| Revenue | 743 K | ||||
| Gross Profit | 810 K | ||||
| EBITDA | (8.18 M) | ||||
| Net Income | (7.63 M) | ||||
| Cash And Equivalents | 12.77 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 40 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (8.44 M) | ||||
| Short Ratio | 1.66 X | ||||
| Earnings Per Share | (2.60) X | ||||
| Target Price | 13.33 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 13.04 M | ||||
| Total Asset | 9.99 M | ||||
| Retained Earnings | (158.48 M) | ||||
| Working Capital | 7.89 M | ||||
| Current Asset | 39.51 M | ||||
| Current Liabilities | 5.77 M | ||||
| Net Asset | 9.99 M |
About Can Fite Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Can Fite Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Can Fite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Can Fite Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Can Fite Piotroski F Score and Can Fite Altman Z Score analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.